MASH VP! Re:VISION is a revolutionary rhythm game that “fuses” two lines and music into a completely new experience. With a variety of tracks, game modes, and a creativity-driven mashup system ...

Released last September with a $130 MSRP, the Zelda: Twilight Princess Complete Box Set contains all 11 volumes in paperback, a double-sided poster, and a decorative display case. Amazon's $57 ...

Racial and ethnic minorities are underrepresented in MASH RCTs, affecting the applicability of trial results to diverse populations. MASH is influenced by genetic, environmental, and social ...

The box set contains the three books of the Lord of the Rings trilogy: The Fellowship of the Ring, The Two Towers, and The Return of the King. The books are illustrated with over 50 full-page ...

Want the music to never stop? There's a new massive Grateful Dead box set just for you. "Enjoying the Ride," is a 60-CD box set encompassing more than 60 hours of music, collected from the iconic ...

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage ...

Here are some of the best Amazon DVD deals and Blu-ray sales right now ... including a new 4K edition. Now, the box set of one of the most rewatchable series of all time is on sale during Amazon ...

The vast majority of performances included on Enjoying the Ride are previously unreleased. The box set features more than 450 tracks, with a running time exceeding 60 hours. The collection boasts ...

It means that the committee can now accept evidence generated by the tool as scientifically valid in future applications and assessments for new MASH treatments. MASH is a condition linked with ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

NEW YORK — Akero Ther­a­peu­tics may not have ad­e­quate da­ta for ac­cel­er­at­ed ap­proval of its MASH drug, de­spite show­ing it may re­verse cir­rho­sis in pa­tients with … ...